Stockreport

Viridian Therapeutics Prepares for Transformational 2026 [Yahoo! Finance]

Viridian Therapeutics, Inc.  (VRDN) 
PDF - Topline phase 3 results for subcutaneous elegrobart (VRDN-003) on track for Q1 2026 for REVEAL-1 and Q2 2026 for REVEAL-2 for active and chronic TED, respectively - [Read more]